Quarterly report pursuant to Section 13 or 15(d)

Liquidity (Details Narrative)

v3.8.0.1
Liquidity (Details Narrative) - USD ($)
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Accumulated deficit $ 55,004,411   $ 33,276,489
Proceeds from sale of stock 41,378,762 $ 15,235,283  
Cash on hand 36,597,469   $ 14,992,257
Cystic Fibrosis Foundation Therapeutics Inc [Member]      
Milestone payment $ 500,000    
Institutional Investors [Member] | October 26, 2017 [Member]      
Number of common stock share sold 4,650,000    
Purchase price per share $ 7.00    
Proceeds from sale of stock $ 32,550,000    
Institutional Investors [Member] | October 2017 Offering [Member] | October 26, 2017 [Member]      
Number of common stock share sold 4,650,000    
Purchase price per share $ 7.00    
Proceeds from sale of stock $ 30,397,000